Johanna Friedl-Naderer

CIK: 0001915598

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)11 (73.3%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (26.7%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

DYN

Dyne Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (15 total)

DYN
Dyne Therapeutics, Inc.
Sep 8, 2026
Sale(S)
Direct
185 shares at avg. $18.88$3K
DYN
Dyne Therapeutics, Inc.
Sep 4, 2026
Sale(S)
Direct
900 shares at avg. $24.35$22K
DYN
Dyne Therapeutics, Inc.
Aug 13, 2026
Sale(S)
Direct
226 shares at avg. $26.28$6K
DYN
Dyne Therapeutics, Inc.
Jun 16, 2026
Sale(S)
Direct
145 shares at avg. $18.33$3K
DYN
Dyne Therapeutics, Inc.
May 13, 2026
Sale(S)
Direct
228 shares at avg. $18.36$4K
DYN
Dyne Therapeutics, Inc.
Mar 5, 2026
Sale(S)
Direct
148 shares at avg. $14.90$2K
DYN
Dyne Therapeutics, Inc.
Feb 12, 2026
Award(A)
Direct
60K shares-
DYN
Dyne Therapeutics, Inc.
Dec 5, 2025
Sale(S)
Direct
144 shares at avg. $20.72$3K
DYN
Dyne Therapeutics, Inc.
Sep 5, 2025
Sale(S)
Direct
144 shares at avg. $13.41$2K
DYN
Dyne Therapeutics, Inc.
Sep 4, 2025
Sale(S)
Direct
894 shares at avg. $13.27$12K
DYN
Dyne Therapeutics, Inc.
Jul 16, 2025
Award(A)
Stock option (right to buy)
Direct
51.3K shares-
DYN
Dyne Therapeutics, Inc.
Jun 5, 2025
Sale(S)
Direct
146 shares at avg. $13.35$2K
DYN
Dyne Therapeutics, Inc.
Mar 13, 2025
Sale(S)
Direct
143 shares at avg. $12.12$2K
DYN
Dyne Therapeutics, Inc.
Dec 4, 2024
Award(A)
Direct
37.8K shares-
DYN
Dyne Therapeutics, Inc.
Sep 3, 2024
Award(A)
Direct
58.4K shares-

		Type	Shares	Price		Ownership
Sep 8, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	185	$18.88	$3,493	Direct
Sep 4, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	900	$24.35	$21,915	Direct
Aug 13, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	226	$26.28	$5,939	Direct
Jun 16, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	145	$18.33	$2,658	Direct
May 13, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	228	$18.36	$4,186	Direct
Mar 5, 2026	DYN Dyne Therapeutics, Inc.	Sale(S)	148	$14.90	$2,205	Direct
Feb 12, 2026	DYN Dyne Therapeutics, Inc.	Award(A)	60,000	-	$0	Direct
Dec 5, 2025	DYN Dyne Therapeutics, Inc.	Sale(S)	144	$20.72	$2,984	Direct
Sep 5, 2025	DYN Dyne Therapeutics, Inc.	Sale(S)	144	$13.41	$1,931	Direct
Sep 4, 2025	DYN Dyne Therapeutics, Inc.	Sale(S)	894	$13.27	$11,863	Direct
Jul 16, 2025	DYN Dyne Therapeutics, Inc.	Award(A) Stock option (right to buy)	51,255	-	-	Direct
Jun 5, 2025	DYN Dyne Therapeutics, Inc.	Sale(S)	146	$13.35	$1,949	Direct
Mar 13, 2025	DYN Dyne Therapeutics, Inc.	Sale(S)	143	$12.12	$1,733	Direct
Dec 4, 2024	DYN Dyne Therapeutics, Inc.	Award(A)	37,800	-	$0	Direct
Sep 3, 2024	DYN Dyne Therapeutics, Inc.	Award(A)	58,400	-	$0	Direct

1-15 of 15 transactions

About Friedl-Naderer Johanna

Friedl-Naderer Johanna (SEC CIK 0001915598) files insider reports with the SEC as Chief Commercial Officer of Dyne Therapeutics, Inc. (DYN).

Signal8 holds 14 ownership filings by Friedl-Naderer Johanna (1 Form 3, 13 Form 4), filed between Sep 3, 2024 and Sep 8, 2026. Those filings report 15 transactions, from Sep 3, 2024 to Sep 8, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Friedl-Naderer Johanna's filings is in WALTHAM, MA.

Recent filings by Friedl-Naderer Johanna

Sep 8, 2026: Open-market sale of DYN shares (Form 4, code S).
Sep 4, 2026: Open-market sale of DYN shares (Form 4, code S).
Aug 13, 2026: Open-market sale of DYN shares (Form 4, code S).
Jun 16, 2026: Open-market sale of DYN shares (Form 4, code S).
May 13, 2026: Open-market sale of DYN shares (Form 4, code S).

Other insiders filing for Dyne Therapeutics, Inc. (DYN)

Kerr Douglas, Head of R&D and CMO
Posner Brian S, Director
Cox John, CEO & President
Rhodes Jason P, Director
Lucera Erick, Chief Financial Officer
Kersten Dirk, Director

How to read Form 4 transaction codes